Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Depreciation and Depletion: 2019-2025

Historic Depreciation and Depletion for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $1.1 million.

  • Avidity Biosciences' Depreciation and Depletion rose 57.14% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 31.04%. This contributed to the annual value of $2.8 million for FY2024, which is 33.27% up from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Depreciation and Depletion is $1.1 million, which was up 37.50% from $800,000 recorded in Q2 2025.
  • Avidity Biosciences' 5-year Depreciation and Depletion high stood at $1.1 million for Q3 2025, and its period low was $100,000 during Q2 2021.
  • For the 3-year period, Avidity Biosciences' Depreciation and Depletion averaged around $691,273, with its median value being $700,000 (2024).
  • Data for Avidity Biosciences' Depreciation and Depletion shows a peak YoY soared of 200.00% (in 2022) over the last 5 years.
  • Over the past 5 years, Avidity Biosciences' Depreciation and Depletion (Quarterly) stood at $208,000 in 2021, then surged by 89.42% to $394,000 in 2022, then soared by 52.54% to $601,000 in 2023, then rose by 26.79% to $762,000 in 2024, then surged by 57.14% to $1.1 million in 2025.
  • Its Depreciation and Depletion was $1.1 million in Q3 2025, compared to $800,000 in Q2 2025 and $800,000 in Q1 2025.